The Oxford Access for Students Improving Sleep (OASIS) study

Conditions

Insomnia in university students Mental and Behavioural Disorders Insomnia

Alasdair L. Henry, Christopher B. Miller, Richard Emsley, Bryony Sheaves, Daniel Freeman et al. (7 authors)

Journal of Affective Disorders2023-06-2911 citations

10.1016/j.jad.2023.06.053

The effects of improving sleep on mental health (OASIS): a randomised controlled trial with mediation analysis.

Freeman D, Sheaves B, Goodwin GM, Yu LM, Nickless A, Harrison PJ, Emsley R, Luik AI, Foster RG, Wadekar V, Hinds C, Gumley A, Jones R, Lightman S, Jones S, Bentall R, Kinderman P, Rowse G, Brugha T, Blagrove M, Gregory AM, Fleming L, Walklet E, Glazebrook C, Davies EB, Hollis C, Haddock G, John B, John B, Coulson M, Fowler D, Pugh K, Cape J, Moseley P, Brown G, Hughes C, Obonsawin M, Coker S, Watkins E, Schwannauer M, MacMahon K, Siriwardena AN, Espie CA.

2017-09-06432 citations

10.1016/s2215-0366(17)30328-0

Effects of cognitive behavioural therapy for insomnia on the mental health of university students: study protocol for a randomized controlled trial.

Freeman D, Sheaves B, Goodwin GM, Yu LM, Harrison PJ, Emsley R, Bostock S, Foster RG, Wadekar V, Hinds C, Espie CA.

2015-05-2825 citations

10.1186/s13063-015-0756-4

Interventions

The treatment arm will receive digital Cognitive Behavioural Therapy for insomnia (in addition to treatment as usual). The control arm will continue with treatment as usual. Participants will not be

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Students (undergraduate, post-graduate or other) screening positive for probable insomnia disorder, using the sleep condition indicator questionnaire (Espie et al., 2014) 2. All participants must be aged 18 or older

Exclusion criteria

Exclusion criteria: Under age 18

Design outcomes

Primary

Measure	Time frame
1. The Sleep Condition Indicator (SCI) will be used as the primary sleep outcome measure. It will be administered at weeks 0, 3, 10 and 22. Week 10 will be the primary endpoint 2. The Green Paranoid Thoughts Scale (GPTS) and the hallucinations subscale of the Specific Psychotic Experiences Questionnaire (SPEQ) will be administered at weeks 0, 3, 10 and 22. Both of these measures will be primary measures to assess sub-clinical levels of mistrust of others (paranoia) and abnormal perceptual experiences (hallucinatory experiences) which are common in the general population. Week 10 will be the primary endpoint	—

Measure

Time frame

1. The Sleep Condition Indicator (SCI) will be used as the primary sleep outcome measure. It will be administered at weeks 0, 3, 10 and 22. Week 10 will be the primary endpoint 2. The Green Paranoid Thoughts Scale (GPTS) and the hallucinations subscale of the Specific Psychotic Experiences Questionnaire (SPEQ) will be administered at weeks 0, 3, 10 and 22. Both of these measures will be primary measures to assess sub-clinical levels of mistrust of others (paranoia) and abnormal perceptual experiences (hallucinatory experiences) which are common in the general population. Week 10 will be the primary endpoint

—

Secondary

Measure	Time frame
1. Depression, measured using the Patient Health Questionnaire 9-item version at weeks 0, 10, and 22 and 2-item version at week 3 2. Anxiety, measured using the Generalised Anxiety Disorder Questionnaire 7-item version at weeks 0, 10, and 22 and 2-item version at week 3 3. Mania, measured using the Altman mania scale at weeks 0, 3, 10 and 22 4. Nightmare severity, measured using the Disturbing Dream and Nightmare Severity Index at weeks 0, 10 and 22 5. Emotional wellbeing, measured using the Warwick-Edinburgh Mental Wellbeing scale at weeks 0, 10 and 22 6. Ultra high risk for psychosis, measured using the Prodromal Questionnaire at weeks 0, 10 and 22 7. Use of services for mental health problems	—

Measure

Time frame

1. Depression, measured using the Patient Health Questionnaire 9-item version at weeks 0, 10, and 22 and 2-item version at week 3 2. Anxiety, measured using the Generalised Anxiety Disorder Questionnaire 7-item version at weeks 0, 10, and 22 and 2-item version at week 3 3. Mania, measured using the Altman mania scale at weeks 0, 3, 10 and 22 4. Nightmare severity, measured using the Disturbing Dream and Nightmare Severity Index at weeks 0, 10 and 22 5. Emotional wellbeing, measured using the Warwick-Edinburgh Mental Wellbeing scale at weeks 0, 10 and 22 6. Ultra high risk for psychosis, measured using the Prodromal Questionnaire at weeks 0, 10 and 22 7. Use of services for mental health problems

—

Countries

United Kingdom

Outcome results

None listed